This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/drug/DB04821/identifier/chemspider/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04821/identifier/chebi/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB04821/identifier/wikipedia/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04821/identifier/bindingdb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/drug/DB04821/identifier/pubchem-compound/
n10http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB04821/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB04821/identifier/drugbank/

Statements

Subject Item
n2:DB04821
rdf:type
n10:Drug
n10:description
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.
n10:group
withdrawn
owl:sameAs
n6:DB04821 n12:DB04821
dcterms:title
Nomifensine
adms:identifier
n4:4371 n7:DB04821 n8:50005548 n9:116225 n14:Nomifensine n17:4528 n18:46505804
n10:synonym
8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline (+)-nomifensine 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine (+)-nomiphensine (+-)-nomifensin 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolin (+-)-nomifensine 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline (R)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine Nomifensina Nomifensin Nomifensinum
n10:toxicity
A likely cause of nomifensine toxicity is the aromatic amine group, as compounds containing this chemical substructure are notorious for producing toxic metabolites.
n10:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Nomifensine.htm
n15:hasConcept
n16:M0014947
n10:IUPAC-Name
n11:271B56B1-363D-11E5-9242-09173F13E4C5
n10:InChI
n11:271B56B7-363D-11E5-9242-09173F13E4C5
n10:Molecular-Formula
n11:271B56B6-363D-11E5-9242-09173F13E4C5
n10:Molecular-Weight
n11:271B56B3-363D-11E5-9242-09173F13E4C5
n10:Monoisotopic-Weight
n11:271B56B4-363D-11E5-9242-09173F13E4C5
n10:SMILES
n11:271B56B5-363D-11E5-9242-09173F13E4C5
n10:Water-Solubility
n11:271B56AF-363D-11E5-9242-09173F13E4C5
n10:logP
n11:271B56AD-363D-11E5-9242-09173F13E4C5 n11:271B56B0-363D-11E5-9242-09173F13E4C5
n10:logS
n11:271B56AE-363D-11E5-9242-09173F13E4C5
n10:H-Bond-Acceptor-Count
n11:271B56BD-363D-11E5-9242-09173F13E4C5
n10:H-Bond-Donor-Count
n11:271B56BE-363D-11E5-9242-09173F13E4C5
n10:InChIKey
n11:271B56B8-363D-11E5-9242-09173F13E4C5
n10:Polar-Surface-Area--PSA-
n11:271B56B9-363D-11E5-9242-09173F13E4C5
n10:Polarizability
n11:271B56BB-363D-11E5-9242-09173F13E4C5
n10:Refractivity
n11:271B56BA-363D-11E5-9242-09173F13E4C5
n10:Rotatable-Bond-Count
n11:271B56BC-363D-11E5-9242-09173F13E4C5
n10:affectedOrganism
Humans and other mammals
n10:casRegistryNumber
24526-64-5
n10:category
n10:Bioavailability
n11:271B56C2-363D-11E5-9242-09173F13E4C5
n10:Ghose-Filter
n11:271B56C4-363D-11E5-9242-09173F13E4C5
n10:MDDR-Like-Rule
n11:271B56C5-363D-11E5-9242-09173F13E4C5
n10:Melting-Point
n11:271B56C6-363D-11E5-9242-09173F13E4C5
n10:Number-of-Rings
n11:271B56C1-363D-11E5-9242-09173F13E4C5
n10:Physiological-Charge
n11:271B56C0-363D-11E5-9242-09173F13E4C5
n10:Rule-of-Five
n11:271B56C3-363D-11E5-9242-09173F13E4C5
n10:Traditional-IUPAC-Name
n11:271B56B2-363D-11E5-9242-09173F13E4C5
n10:pKa--strongest-basic-
n11:271B56BF-363D-11E5-9242-09173F13E4C5